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In mammalian cells, the E2F family of transcription factors plays
a pivotal role in regulating the expression of genes involved in
the G1/S transition and DNA synthesis. In turn, E2F activity is
controlled primarily by the retinoblastoma (pRB) family of pro-
teins. Much is known about the regulation of E2F by pRB in the
context of the cell cycle, and several reviews have provided
excellent coverage of these topics (Dyson, 1998; Harbour and
Dean, 2000; Trimarchi and Lees, 2002). This review will focus
instead on recent findings suggesting diversification within the
E2F family that allows the execution of specialized functions in
response to various cellular cues that promote or inhibit prolifer-
ation. In particular, technical innovations have brought new
insights regarding the roles for E2F family members beyond the
G1-to-S transition and suggest that E2F contributes to the DNA
damage and repair checkpoint response and tumorigenesis.
A role for E2F in repression versus activation
Current evidence suggests that there is a clear bifurcation of
E2F family members with respect to their transcriptional roles in
cell cycle control: E2F1–3 function mainly as activators of tran-
scription while E2F4 and E2F5 act primarily as repressors.
Hence, we refer to the activator and repressor classes of E2Fs
(Figure 1A). The divergence of function between the two class-
es of E2F parallels their specificity of binding to the pRB family
of proteins: E2F1–3 bind only to pRB, E2F5 binds to p130, and
E2F4 can bind to all three pRB members (Figure 1B). E2F6 dif-
fers significantly from the other E2Fs, and since its role as a
transcriptional repressor has not been as thoroughly investigat-
ed, it will be excluded from general discussion in this review. A
more extensive summary of evidence in support of this current
picture of the E2F family has been provided elsewhere
(Trimarchi and Lees, 2002).
Promoter occupancy by E2F in vivo
In serum-deprived cells, E2F-responsive promoters are occu-
pied exclusively by complexes containing E2F4, p130, and a
histone deacetylase (HDAC)-associated corepressor complex
(Rayman et al., 2002; Ren et al., 2002; Takahashi et al., 2000)
(Figure 1C). As cells reenter the cell cycle and progress through
mid-G1, E2F4 and p130 and the entire corepressor complex are
displaced by the activators E2F1, 2, and 3, coincident with the
induction of E2F-responsive genes (Rayman et al., 2002;
Takahashi et al., 2000). These data are wholly consistent with
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the view that there are two distinct subgroups within the E2F
family: E2F4 and E2F5 act as repressors of E2F transcription in
quiescent and early G1 cells by associating with the pocket pro-
teins, while E2F1, 2, and 3, devoid of associated pocket pro-
teins, function as activators in late G1 and S phase. Importantly,
these studies also suggested that occupancy of E2F-respon-
sive promoters by repressive and activating E2Fs is sequential
and mutually exclusive. Remarkably, a similar division of labor
among distinct E2F family members has also been demonstrat-
ed recently in Drosophila (Stevaux et al., 2002).
Recent analysis of approximately 1400 proximal human
promoters revealed E2F binding to a much larger set of cell
cycle-regulated promoters than anticipated (Ren et al., 2002).
Significantly, these target genes function not only during the
G1/S transition and DNA replication but also during mitosis and
in DNA damage and repair checkpoints. A number of these
novel E2F targets were shown to be controlled by the
E2F4/p107/p130 repressive complex since they were notice-
ably deregulated in p107−/−; p130−/− mouse embryonic fibrob-
lasts (MEFs) (Ren et al., 2002). Therefore, current data suggest
a more prominent role for E2F in repression of the cell cycle
machinery during G0 and early G1. Whether the activator E2Fs
contribute equally to the activation of these novel E2F targets
remains to be seen. However, it is likely that a number of them,
such as those involved in DNA repair, are regulated by the acti-
vator E2Fs since their promoters were occupied by E2F1 during
G1 and they were responsive to induction by E2F1 and E2F2
(Ishida et al., 2001; Ren et al., 2002).
Proliferation and cell cycle exit defects in E2F knockout
cells
More recent evidence bolstering the view of functional divisions
within the E2F family has been obtained from mouse knockout
experiments. In E2F3-deficient MEFs, many known E2F-
responsive genes are not upregulated in quiescent cells
responding to mitogen stimulation, suggesting a requirement
for E2F3 in transcriptional activation (Humbert et al., 2000b).
Consequently, the rate of proliferation of both primary and trans-
formed cells is reduced (Humbert et al., 2000b). Moreover,
MEFs that are deficient for all three “activating” E2Fs display
proliferative arrest, and E2F target genes critical for the G1/S
transition and DNA replication are not appropriately induced
(Wu et al., 2001). Furthermore, loss of E2F3, but not E2F1,
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E2F2, E2F4, or E2F5, results in deregulated cyclin E-depen-
dent kinase activity, defects in nucleophosmin B association
with centrosomes, and premature centriole separation and
duplication (Saavedra et al., 2003).
In contrast, cells lacking E2F4, E2F5, or both do not display
cell cycle perturbations or aberrant gene expression (Humbert et
al., 2000a; Rempel et al., 2000). However, these cells do not
properly respond to growth-inhibitory signals provoked by p16
overexpression, and the fact that similar results were obtained
with p107−/−;p130−/− MEFs reinforces conclusions from recent
ChIP studies indicating that E2F4 and E2F5, in association with
p107 and/or p130, are the primary repressors of E2F target
genes (Bruce et al., 2000; Hurford et al., 1997; E. Balciunaite and
B.D.D., unpublished data). These results may also explain why
mice lacking E2f4, E2f5, p107, or p130 individually or in combi-
nation tend to suffer developmental abnormalities presumably
related to defects in cell cycle exit prior to terminal differentiation.
E2F and DNA damage
Data from E2F knockout mice suggested that activator E2Fs are
not only essential for cell proliferation but that they also play a
role in apoptosis (Field et al., 1996;Yamasaki et al., 1996). How
E2F triggers apoptosis is not clear. Several studies have
focused on E2F-mediated apoptosis via p53/p14ARF pathways
(Ginsberg, 2002). One recent study suggested that direct inter-
action of the cyclin A binding domain of E2F1 with p53 was able
to induce apoptosis in response to DNA damage (Hsieh et al.,
2002), while another demonstrated that p53 phosphorylation
was critical for E2F1-mediated apoptosis (Rogoff et al., 2002).
Intriguingly, E2F1 might play a more direct role in apoptosis:
overexpression of E2F1, like loss of pRB function through E1A
or mutation, induced caspase expression, provoking apoptosis
and suggesting that activator E2Fs can be effectors of cell
death signals (Nahle et al., 2002).
Several recent studies suggest an additional role for E2F1
in a DNA damage checkpoint and apoptosis (Huang et al.,
1997; Lin et al., 2001; Maser et al., 2001). In one study, ionizing
radiation led to the upregulation of E2F1 protein, induction of S
phase, and subsequent cell death (Huang et al., 1997), and a
second report showed that cells treated with a DNA-damaging
agent stabilized E2F1 levels (Lin et al., 2001). Stabilization of
E2F is thought to be due to phosphorylation of E2F1 by the
ataxia-telangiectasia mutated (ATM) and ataxia-telangiectasia
and Rad3-related (ATR) kinases (Lin et al., 2001). The
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Figure 1. Structural divergence and preferential pRB binding explain cell cycle timing of promoter occupancy among E2F proteins
A: The E2F family contains six members that can be divided into at least two subgroups: E2F1–3 function primarily as activators of transcription, while E2F4
and E2F5 as repressors of transcription, and E2F6, which lacks a transactivation domain altogether, is likely to be involved in gene silencing. NES (nuclear
export signal); NLS (nuclear localization signal).
B: Selective E2F binding to pRB family proteins.
C: Sequence and timing of target gene promoter occupancy by repressor and activator E2Fs is illustrated.
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ATM/ATR phosphorylation site is unique to E2F1 and lies in the
amino-terminal region of E2F1 that overlaps with the p45SKP2
binding site, suggesting that E2F1 phosphorylation by ATM/ATR
kinases may confer resistance to p45SKP2-mediated degradation
of E2F1 (Lin et al., 2001; Marti et al., 1999).That E2F1 may play
a role in an S phase checkpoint was suggested previously by
experiments in which expression of a stabilized form of E2F1
provoked an S phase delay and apoptosis (Krek et al., 1995).
Stabilization of E2F1 during S phase may trigger a sensor for
abnormally elevated E2F activity that could lead to an apoptotic
response similar to that observed in cells overexpressing acti-
vator E2Fs (DeGregori et al., 1997). Interestingly, E2F1 has
also been implicated recently in the recruitment of NBS1 and
the MRE11 recombination/repair complex to origins of DNA
replication where it may implement activation of a checkpoint by
suppressing origin firing when cells entering S phase are irradi-
ated (Maser et al., 2001).
These findings are intriguing in light of other recent obser-
vations. First, pRB has been shown to regulate progression
through S phase, at which point it is necessary for cell cycle
arrest in response to DNA damage (Knudsen et al., 1998;
Knudsen et al., 2000). In addition, recent ChIP studies suggest
that pRB is not present at E2F-responsive promoters in cycling
cells (Rayman et al., 2002; Takahashi et al., 2000), inviting
speculation that this protein may act as a tumor suppressor at
least in part by virtue of its localization to other regulatory
regions, such as origins. Certain cues, such as cell cycle with-
drawal induced by p16 overexpression or terminal differentia-
tion, might cause pRB to relocalize to promoters (Dahiya et al.,
2001; Thomas et al., 2001). Other work, however, directly impli-
cates a role for pRB during S phase (Bosco et al., 2001;
Kennedy et al., 2000). In particular, Bosco et al. recently demon-
strated a requirement for RBF (a pRB homolog) binding to dE2F
to enforce normal origin function in Drosophila (Bosco et al.,
2001). Although much work will be needed to fully understand
the mechanisms through which E2F1 (and pRB) could enforce
a potential checkpoint, it is tempting to speculate that enhanced
E2F1 levels may be one sensor that prevents further cell cycle
progression by recruitment of proteins that suppress origin fir-
ing or by inappropriately elevating target gene expression and
thereby engaging an apoptotic pathway, or both. Regardless of
the mechanism, these studies illustrate how E2F1 and their reg-
ulators play a central role in control of both cell cycle progres-
sion and genome integrity and how the loss of appropriate
responses promotes tumorigenesis.
Consistent with these observations, mouse embryos lack-
ing Rb display numerous apoptosis-induced developmental
defects, which were dramatically alleviated in the absence of
either E2F1 or E2F3 (Yamasaki et al., 1998; Ziebold et al.,
2001). However, it is not clear whether or how the role of E2F1
in S phase-induced apoptosis is related to suppression of origin
firing by E2F1, and possibly other E2Fs. Intriguingly, recent
expression profiling and location analyses have identified more
than a dozen E2F targets, including p53, chk1, pcna, fen1 that
are known to be involved in the DNA damage response, hinting
at a pervasive involvement of E2F in a DNA damage response
pathway (Ishida et al., 2001; Muller et al., 2001; Polager et al.,
2002; Ren et al., 2002). In addition, a cohort of genes involved
in DNA repair was also identified as targets of E2F4 (Ren et al.,
2002), inviting speculation that a tight coupling of DNA replica-
tion and repair in mammalian cells requires the E2F family.
Furthermore, a more general requirement for repressive E2F
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Figure 2. Cellular processes that involve E2F regulation
Recent gene profiling and location analysis experiments suggest more extensive control by E2F family members than originally anticipated: E2F plays a role
in regulating genes involved not only in S phase entry, but DNA repair and mitosis as well.
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activity in growth arrest associated with TGFβ signaling, contact
inhibition, p16, and p19ARF/p53-dependent senescence has
been demonstrated (Rowland et al., 2002; Zhang et al., 1999).
Although the complex circuitry through which these E2F targets
are regulated by the two subclasses of E2F needs further study,
it is nevertheless clear that E2F plays a more pervasive role
than anticipated in processes other than S phase entry (Figure 2).
E2F and tumorigenesis
Recent studies have also shed new light on the connections
between E2F, apoptosis, and tumorigenesis. Overexpression
of activator E2Fs is not only able to drive cells out of quies-
cence, but in some settings, it also confers transforming
potential to primary cells (Pierce et al., 1998; Trimarchi and
Lees, 2002). Several lines of evidence support the view that
pRB-E2F interactions play a
major role in restraining E2F
oncogenic activity. First,
inactivation of pRB function
by viral oncoproteins or can-
cerous mutations also tends
to prevent pRB binding to
E2F (Sellers and Kaelin,
1996). Second, overexpres-
sion of E2F mutants that
cannot bind pRB promotes
anchorage- independent
growth more efficiently than
wild-type E2F1 (Xu et al.,
1995). Finally, loss of E2F1
in Rb+/− mice partially sup-
presses the incidence of
pituitary and thyroid tumors
(Yamasaki et al., 1998).
Whether loss of the other
activator E2Fs such as E2F2
and E2F3 also contributes to
tumor suppression in Rb+/−
mice has yet to be deter-
mined. However, Ziebold et
al. recently reported that
E2F3 loss in Rb−/− mice
rescues most of the abnor-
mal proliferation and apop-
tosis associated with Rb−/−
embryos (Ziebold et al.,
2001). This phenotype is
reminiscent of Rb−/−;E2f1−/−
mouse embryos in which
loss of E2F1 suppressed
almost all of the p53-depen-
dent apoptosis associated with Rb−/− embryos (Tsai et al., 1998).
Therefore, it is tempting to speculate that E2F3 loss might simi-
larly contribute to a lower incidence of pituitary and thyroid
tumors in mice simultaneously deficient for pRB. These results
are especially interesting in light of recent data indicating that
apoptosis observed in Rb null embryos stems from placental
defects (Wu et al., 2003). However, these non-cell-autonomous
roles for pRB in neurogenesis and erythropoiesis are likely to
be different from its known function as a tumor suppressor since
all pituitary tumors in chimeric mice originate strictly from Rb−/−
cells (Maandag et al., 1994; Williams et al., 1994).
The role of E2F as an oncogenic factor in tumorigenesis is
firmly established. However, a report that adult E2f1−/− mice
developed a broad spectrum of tumors was unanticipated, sug-
gesting that E2F1 has a dual role in tumorigenesis both as an
oncogene and as a tumor suppressor (Field et al., 1996;
Yamasaki et al., 1996). Interestingly, the types of tumors present
in E2f1−/− mice are distinct from Rb+/− mice: whereas Rb+/− mice
consistently develop pituitary adenomas and thyroid tumors,
E2f1−/− mice develop reproductive tract sarcomas, lymphoma,
and lung tumors. Therefore, E2F1 loss may not be equivalent to
pRB loss as an underlying cause of tumor appearance in E2f1−/−
mice. Since E2F1 has been implicated in p53-dependent apop-
tosis, it is now thought that E2F1 tumor suppressor function
could at least partly stem from its ability to relay apoptotic sig-
nals to p53 (Pan et al., 1998). E2F2 may also act as a tumor
suppressor since E2F2 defi-
ciency further predisposes
E2f1−/− mice to additional
tumor development (Zhu et
al., 2001).
While several recent
reports have begun to clarify
the roles of activator E2Fs in
tumorigenesis, little was
known about the tumorigenic
roles of repressor E2Fs. Mice
deficient for various combina-
tions of E2f4 and E2f5 have
been generated. These stud-
ies suggest that besides
developmental defects in cer-
tain lineages, E2F4-deficient
mice are tumor free (Gaubatz
et al., 2000; Humbert et al.,
2000a; Rempel et al., 2000).
Although E2F5−/− mice are
born with hydrocephalic syn-
drome, they are viable, but
most died after 6 weeks, pre-
venting the study of the role
of E2F5 in tumor suppression
(Lindeman et al., 1998).
Predictably, E2f4−/−;E2f5−/−
mice died as neonates mak-
ing it impossible to assess
the compound loss of both
E2F4 and E2F5 on tumorige-
nesis (Gaubatz et al., 2000).
pRB binds both to activa-
tor E2Fs and E2F4, the prin-
cipal repressor E2F. How or if
the pRB-E2F4 interaction contributes to tumor suppression is
not clear. However, recent work has begun to address this ques-
tion (Lee et al., 2002). Given the role of E2F4 as a major tran-
scriptional repressor, the expectation would be that compound
loss of this gene and Rb would exacerbate the tumor pheno-
type. Surprisingly, Rb+/−;E2f4−/− mice were virtually tumor free up
to 14 months of age. This finding is remarkable given that most
Rb+/− mice died at or before 11 months of age due to pituitary
and thyroid tumors (Yamasaki et al., 1998). Several older 
Rb+/−;E2f4−/− mice eventually developed pituitary tumors, but the
tumor severity varied widely among them (Lee et al., 2002).
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Figure 3. Current model for how E2F contributes to tumorigenesis and tumor
suppression
Elevated levels of activator E2Fs can trigger apoptosis via p53-dependent
or p53-independent pathways. Unrestrained activity of activator E2Fs,
which are essential for proliferation of mammalian cells, results from the
absence of pRB and leads to tumorigenesis. While E2f3 loss suppresses
apoptosis associated with simultaneous Rb loss, unlike the E2f1 knockout, it
does not exhibit tumor suppressor activity (dotted line). Although abun-
dant evidence exists for the importance of E2F4 and E2F5 in cell cycle exit
associated with enforced expression of p16 or cellular differentiation,
whether the combined activities of E2F4 and E2F5 can function in tumor
suppression is not known.
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Examination of the pocket protein-E2F complexes in various
organs and MEFs of Rb+/−;E2f4−/− mice revealed that loss of
E2F4 promotes formation of novel complexes between p107
and p130 and the activator E2Fs that could suppress improper
E2F activity in the absence of Rb. These novel complexes prob-
ably have a repressive effect on E2F-responsive promoters
since appropriate transcription of the cyclin E gene, which is
deregulated in Rb−/− MEFs, was restored in Rb−/−;E2f4−/− MEFs
(Lee et al., 2002). p130 was also detected in complexes with
E2F5 in Rb−/−;E2f4−/− MEFs. However, it is unlikely that the
p130/E2F5 complex is responsible for repressing cyclin E tran-
scription because in the absence of Rb alone, there is an abun-
dance of the p130/E2F4 complex, which functionally resembles
the p130/E2F5 complex. Interestingly, compound loss of E2F4
and E2F5 enhanced p107 and p130 association with the activa-
tor E2Fs (Lee et al., 2002; H.C., J. Rayman, and B.D.D., unpub-
lished data), which could explain why E2f4−/−;E2f5−/− MEFs do
not display deregulation of E2F activity and therefore no cell
cycle defects in cycling and serum-starved cells (Gaubatz et al.,
2000). Apparently, in the absence of the E2F4 and E2F5 repres-
sors, p107 and p130 are still capable of forming repressor com-
plexes by binding to the activator E2Fs, enabling their
recruitment to, and inhibition of, E2F-responsive promoters
(H.C., J. Rayman, and B.D.D., unpublished data). Taken togeth-
er, these findings also suggest that pRB may be the only pocket
protein with tumor suppressor activity by virtue of the fact that it
is uniquely able to sequester and inhibit activator E2Fs.
Conclusions and perspectives
The initial discovery of E2F and work that followed suggested
that this transcription factor promoted proliferation by activating
critical target genes required for DNA replication. Another key
discovery, the association of E2F with the pRB family, suggested
a simple way in which E2F activity could be restrained until it was
required for gene activation. Recent studies have clearly demon-
strated that E2F family members are not simply activators held in
check. Rather, a subset of the E2F family members function as
active repressors that are subsequently replaced by a new set of
polypeptides that function as activators. Moreover, several
recent studies have considerably expanded our understanding
of the roles of E2F in transcriptional regulation of the cell cycle
and how its mechanisms of transcriptional activation and repres-
sion contribute to tumor formation. Surprisingly, given the known
roles of the two subfamilies of E2F in transcription, current data
suggest that while activator E2Fs can behave both as onco-
genes and tumor suppressors, the repressors E2F4 and E2F5
have no direct effect in tumorigenesis (Figure 3). This is hard to
reconcile with known properties of E2F4 and E2F5 as the prima-
ry repressors of E2F activity. However, given that pRB is the only
tumor suppressor of the pocket protein family and the only one
that normally binds to all three activator E2Fs, it is possible that
repressor E2Fs are essential only in cell cycle exit that occurs
during terminal differentiation (Figure 3). Indeed, mouse knock-
out experiments suggest that the ability of pRB, but not
p107/p130, to exclusively inhibit activator E2Fs under normal
conditions underlies its unique role as tumor suppressor.
However, additional knockout experiments will be required to
determine whether E2F4 and E2F5 play a role as activators as
well as repressors of transcription in other settings since both of
these proteins possess transactivation domains (Figure 1A).
Advances in DNA microarray technology and the combined
use of location analysis and gene expression profiling will
enable the identification of the complete set of physiological tar-
gets of all E2F and pRB family members and will illuminate the
role of E2Fs not only in the control of replication and tumorigen-
esis but also in other processes not discussed in this review,
including development and differentiation and how these
processes interconnect (Figures 2 and 3). Significantly, the
recent implication of E2F in the DNA damage response path-
way and the identification of a number of E2F targets involved in
DNA damage and repair by expression and location analysis
strongly suggest a more extensive involvement of E2F in this
pathway. Future studies should be able to dissect the relative
contribution of E2F activation and repression in DNA damage
and repair pathways and explain how its involvement in these
pathways is related to other processes such as apoptosis. Such
an analysis will enable us to link cell cycle events with apopto-
sis, and ultimately, with the failure of surveillance and apoptotic
mechanisms that are known to give rise to tumors.
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